Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Estrella Immunopharma Q3 2026 Results: Net Loss of $7.38M, Loss Widens

Estrella Immunopharma reported a net loss of $11.98 million for the nine months ended September 30, 2026, compared to $12.45 million in the prior year period. The company's cash position decreased significantly to $92,458, while total stockholders' deficit widened to $13.97 million as research and development expenses remained the primary driver of operating costs.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-7.4-4.8
Net income-7.4-4.8
EPS (diluted, $ a share)$-0.17$-0.13

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ESLA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Estrella Immunopharma, Inc.: key numbers

Share price
$0.3800Close, Nov 16
Market cap
$16.7M
Shares outstanding
43.97MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Estrella Immunopharma, Inc.

All →
5:28 PM ET 8-K
Leadership Change

Estrella Immunopharma Leadership Change

Estrella Immunopharma appointed Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board, effective October 25, 2026. She succeeds Cheng Liu, Ph.D., who transitioned to the role of Chief Scientific Officer while remaining President and a director. Ms. Pussinen's employment agreement includes an initial base salary of $250,000 with automatic increases tied to future funding milestones.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.